News - Medicinapersonalizada

"Long-term follow-up has demonstrated the effectiveness of blocking the GDF-15 protein with the monoclonal antibody visugromab in 15% to 20% of patients with advanced cancers who were no longer responding to conventional immunotherapy and had no other therapeutic options available. This is the main finding of an international study sponsored by the German pharmaceutical company CatalYm, led by the Cancer Center Clínica Universidad de Navarra (CCUN) and involving several Spanish hospitals."

Researchers at Cima Universidad de Navarra, in collaboration with Navarra University Hospital (HUN) and Navarrabiomed, have demonstrated that genomic analysis of circulating DNA in bile using ultra-low-pass whole-genome sequencing (ULP-WGS) provides valuable complementary information for the management of patients with biliary strictures.

Annogen, a leader in making gene therapies safer and more effective through advanced gene expression engineering, today announced a new research collaboration with the Cima Universidad de Navarra, a leading Spanish biomedical research center. The partnership, led by Dr. Gloria González-Aseguinolaza and Dr. Rafael Aldabe from CIMA, will leverage Annogen's proprietary SuRETM platform for in vivo screening using CIMA's proprietary in vivo cell-specific kidney delivery system to identify and characterize highly specific promoters for kidney-targeted gene therapy.

The results achieved by SENSORFIT-4HEART confirm the effectiveness of a physical exercise programme and a remote monitoring platform in improving functional capacity and quality of life among patients with heart failure with preserved ejection fraction. These findings were presented by the consortium led by Navarrabiomed-Miguel Servet Foundation, which brought together Navarra University Hospital, Cima Universidad de Navarra, the technology centre NAITEC, the companies Lorpeland and 540, as well as ADItech, in a multidisciplinary partnership combining clinical and biomedical research with technological development. The project was co-funded by the European Regional Development Fund (ERDF) through Navarra's ERDF 2021-2027 Programme, and by the Department of Industry and of Business Ecological and Digital Transition through its 2023-2026 call for strategic R&D projects, which awarded funding of EUR 1.14 million.

"A scientific, technological and industrial consortium bringing together the research centres Cima Universidad de Navarra and Navarrabiomed, the healthcare institutions Clinica Universidad de Navarra and Navarra University Hospital, SINAI agents including Nasertic and Aditech, and leading Navarre-based companies such as 3P Biovian and Neuraraptic AI, has identified tumour-specific T-cell receptors (TCRs) for the development of personalised cell therapies. The breakthrough was achieved through the use of advanced single-cell sequencing technologies and Artificial Intelligence tools. The project was supported by a EUR 1.6 million grant from the Department of Industry and Business Ecological and Digital Transition."

Professionals from the Medical Oncology and Pharmacy departments of Navarra University Hospital (HUN/NOU), in collaboration with the Translational Medical Oncology Unit at Navarrabiomed and IdiSNA, have published a paper describing the centre's experience in optimising immunotherapy treatments for patients with gastrointestinal cancers.